Article Text

THU0511 Update on the Juvenile Systemic Sclerosis Inception Cohort.
  1. I. Foeldvari1,
  2. M. Katsicas2,
  3. M. Teresa Terreri3,
  4. R. Cimaz4,
  5. M. Kostik5,
  6. F. Sztajnbok6,
  7. D. Nemcova7,
  8. M. Moll8,
  9. M. Jose Santos9,
  10. T. Avcin10,
  11. J. Brunner11,
  12. S. Nielsen12,
  13. T. Kallinich13,
  14. K. Minden13,
  15. J. Mueller14,
  16. M. Janarthanan15,
  17. Y. Uziel16,
  18. W.A. Sifuentes-Giraldo17,
  19. D. Eleftheriou18,
  20. K. Torok19,
  21. N. Helmus1
  1. 1Hamburg Center for Pediatric and Adolescent Rheumatology, Am Schön Klinik Eilbek, Hamburg, Germany
  2. 2Hospital de Pediatria, Buenos Aires, Argentina
  3. 3Universidade Federal de São Paulo, Sao Paulo, Brazil
  4. 4Meyer Children's Hospital, Florence, Italy
  5. 5Saint-Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation
  6. 6Universidade do Estado, Rio de Janeiro, Brazil
  7. 7Department of Pediatrics and Adolescent Medicine, Prague, Czech Republic
  8. 8Pediatric Rheumatology, Tuebingen, Germany
  9. 9Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal
  10. 10University Children's Hospital, Ljubljana, Slovenia
  11. 11Pediatric Rheumatology, Innsbruck, Austria
  12. 12Rigshospitalet, Copenhagen, Denmark
  13. 13Charite, Berlin
  14. 14St. Elisabethen Krankenhaus, Loerrach, Germany
  15. 15Pediatric Rheumatology, Chennai, India
  16. 16Meir Medical Center, Kfar Saba, Israel
  17. 17University Hospital Ramόn y Cajal, Madrid, Spain
  18. 18Great Ormond Street Children's Hospital, London, United Kingdom
  19. 19Children's Hospital, Pittsburgh, United States


Background Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Currently just retrospective data exist regarding evolvement of organ involvement. In the previous retrospective studies assessment of the organ involvement was not standardized. Our project is the first one, where data of jSSc patientes were collected prospectively and with a standardized assessment.

Objectives To learn about the characteristics and evolvement of organ involvement in jSSc

Methods Patients with jSSc were recruited worldwide and were prospectively assessed, using the proposed standardized patient assessment protocol. Data of the juvenile systemic sclerosis inception cohort have been contributed to the DeSScipher project which was funded by a grant of theEuropean Community's Framework Programme 7 under grant agreement N° 305495.”

Results 44 centers from 24 countries aggreed to participate on the project. The assent and consent forms were translated into the local native languages. Untill now 39 patients have been enrolled with a mean disease duration of 6.1 years. Thirty (77%) of the 39 patients were females. The mean age of the onset of Raynaud's phenomenon was 9.7 years (2-16 years), the youngest 2 years old. The mean age at the onset of the non-Raynaud presentation of jSSc was 10.3 years (3.0-16.00years). 29 (74%) of the 39 have diffuse subtype. 5 in the diffuse (17%) and 3 in the limited subtype (30%) had an overlap feature.

At the time of the inclusion the mean modified Rodnan Skin Score was 16.5. 26/37 had already capillary changes and 22/37 already history of ulcerations, 9/37 had active ulcerations at the time of the inclusion. 26/39 had cardiopulmonary involvement, 11/39 presented with signs of interstitial lung disease on imaging. Two patients had pulmonary hypertension. Three had renal involvement, but no renal crisis. 16/39 had gastrointestinal involvement and 11 of them esophageal involvement. 30/38 had musculoskeletal involvement. ANA positivity occurred in 30/36 and 12/30 of them were anti-Scl 70 positive. 1/23 had anticentromere positivity.

Conclusions We present the data on the first 39 patients with jSSc included in our cohort. The current recruitment data confirms that pediatric patients are different from the adult patients, with a higher proportion of diffuse subset patients with 74% and of patients with overlap features.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.